Consumer life sciences sits at the intersection of three forces that have been building for a decade: the democratisation of biological data, the mainstreaming of health optimisation, and the collapse of the line between consumer and patient.
What changed
Ten years ago, the consumer relationship with healthcare was largely passive. Patients received diagnoses and prescriptions. The flow of information moved in one direction — from clinician to patient — and the data generated by that interaction stayed inside the healthcare system.
That model is breaking down across several dimensions simultaneously.
The data layer
Direct-to-consumer genomics, continuous glucose monitors, wearable biosensors, and at-home diagnostics have created a new category of health data that exists entirely outside the traditional healthcare system. This data is generated by consumers, owned by consumers, and increasingly acted on by consumers without clinical intermediation.
What this means for capital
The investment implications are significant. Categories that were previously classified as wellness — nutrition, sleep, fitness, stress management — are acquiring clinical evidence bases. The line between supplement and pharmaceutical is blurring at the regulatory level as much as the consumer level.
Novitor tracks these developments across clinical trial registries, capital markets data, and consumer signals — three times per week.